1
|
Malagnino V, Cozzi-Lepri A, Svicher V, Girardi E, Perno CF, Saracino A, Cuomo G, Rusconi S, Puoti M, D'Arminio Monforte A, Andreoni M, Sarmati L. Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy. HIV Med 2024. [PMID: 38837593 DOI: 10.1111/hiv.13680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 05/17/2024] [Indexed: 06/07/2024]
Abstract
OBJECTIVES The aim of this analysis was to investigate the impact of hepatitis B virus (HBV) coinfection on the risk of HIV viral rebound (VR) after achieving suppression for the first time following initiation of antiretroviral therapy (ART) in the real-world setting. DESIGN Patients living with HIV (PLWH) who were enrolled in the ICONA Foundation Study cohort and achieved viral suppression ≤50 copies/mL for the first time after starting ART were prospectively evaluated and divided in three exposure groups according to serology test results: (a) HIV-monoinfected; (b) HIV-positive/HBcAb-positive/HBsAg-negative; (c) HIV-positive/HBsAg-positive. The occurrence of VR, defined as two consecutive HIV-RNA values >50 copies/mL after achieving viral suppression for the first time (baseline), was investigated. METHODS Standard survival analysis by means of Kaplan-Meier curves and Cox regression analysis with the serology exposure fitted as a time-fixed covariate measured at baseline was employed after controlling for key confounding factors. RESULTS Of a total of 5657 patients included, 4090 (72%) were HIV-monoinfected, 1342 (23.7%)were HBcAb-positive, and 225 (3.9%) were HbsAg-positive coinfected. Overall, 654 (11.5%) PLWH experienced VR > 50 copies/mL during follow-up. After controlling for all sources of measured confounding, coinfected PLWH showed an increased risk of experiencing VR compared with those who were HIV-monoinfected. In particular, the strongest associations were seen for the HIV/HBsAg-positive participants [adjusted hazard ratio (aHR) = 1.56, 95% confidence interval (CI): 1.03-2.38, p = 0.037] but an excess of risk was also seen in those who were HIV-positive/HBcAb-positive/HBsAg-negative (aHR = 1.25, 95% CI: 1.00-1.55, p = 0.047). CONCLUSIONS Coinfection with HBV seems to have an impact on the probability of maintaining HIV viral suppression achieved for the first time after ART initiation. Of note, even PLWH positive for HBcAb, a marker of inactive HBV infection, appeared to be at higher risk of VR compared with those who were HIV-monoinfected and their HIV-RNA should be carefully monitored.
Collapse
Affiliation(s)
- Vincenzo Malagnino
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Alessandro Cozzi-Lepri
- Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, London, UK
| | | | - Enrico Girardi
- National Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospitaller and Care Institutions, Scientific Direction, Rome, Italy
| | - Carlo Federico Perno
- Microbiology and Diagnostic Immunology Unit, Department of Diagnostic and Laboratory Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Annalisa Saracino
- Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Policlinic of Bari, Bari, Italy
| | - Gianluca Cuomo
- Clinic of Infectious Diseases, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy
| | - Stefano Rusconi
- Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, Università degli studi Di Milano, Legnano, Italy
| | - Massimo Puoti
- Department of Infectious Diseases, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | | | - Massimo Andreoni
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Loredana Sarmati
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| |
Collapse
|
2
|
Malagnino V, Mulas T, Teti E, Basso M, Giobbia M, Geremia N, Battagin G, Abi Aad Y, Vincensini JP, Iannetta M, Parisi SG, Sarmati L, Lacombe K. HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch. Viruses 2024; 16:348. [PMID: 38543714 PMCID: PMC10974397 DOI: 10.3390/v16030348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 02/19/2024] [Accepted: 02/21/2024] [Indexed: 05/23/2024] Open
Abstract
Hepatitis B Core antibody (HBcAb) positivity is the surrogate marker of hepatitis B occult infection. This condition is not a contraindication for switching to two-drug (2DR) antiretroviral therapy; however, the removal of tenofovir may contribute to poor control of HBV replication. A multicentre retrospective cohort study investigated the impact of HBcAb positivity on HIV control in patients switching to a 2DR with Lamivudine and Dolutegravir (3TC-DTG). In this study, a comparison analysis was conducted between HBcAb-positive and -negative PLWH regarding HIV-RNA suppression, considering: (1): Target Not Detected (TND) < 20 cp/mL; (2) Target Detected (TD) < 20 cp/mL; and (3) Detectable > 20 cp/mL and <50 cp/mL and >50 copies/mL. A total of 267 patients on 2DR with 3TC-DTG were included. In comparison to HBcAb-negative, HBcAb-positive patients were older (45 years [35-54]) and had a lower CD4+ nadir (248 vs. 349 cells/mmc, p = 0.007). No difference in the maintenance of virological suppression was present in the two groups of patients before the switch. Although no patient had an HIV-RNA > 20 cp/mL after the switch, significantly fewer HBcAb-positive compared with -negative subjects resulted in TND at 12, 24, and 36 months after the switch: 52 (69.3%) versus 164 (85.4%), p = 0.004, 50 [72.5%] versus 143 [89.9%], p = 0.001, and 30 [66.7%] versus 90 [92.8%], p = 0.001, respectively. HBcAb positivity is associated with an increased risk of suboptimal HIV suppression during the 36 months after 3TC/DTG simplification. This finding reinforces the relevance of the OBI condition in PLWH and raises the issue of careful virological monitoring of such cases.
Collapse
Affiliation(s)
- Vincenzo Malagnino
- Infectious Disease Unit, Policlinico Tor Vergata of Rome, 00133 Rome, Italy; (T.M.); (E.T.); (M.I.); (L.S.)
- Department of System Medicine, Tor Vergata University of Rome, 00133 Rome, Italy
| | - Tiziana Mulas
- Infectious Disease Unit, Policlinico Tor Vergata of Rome, 00133 Rome, Italy; (T.M.); (E.T.); (M.I.); (L.S.)
| | - Elisabetta Teti
- Infectious Disease Unit, Policlinico Tor Vergata of Rome, 00133 Rome, Italy; (T.M.); (E.T.); (M.I.); (L.S.)
| | - Monica Basso
- Department of Molecular Medicine, University of Padova, 35128 Padova, Italy; (M.B.); (S.G.P.)
| | - Mario Giobbia
- Infectious Disease Unit, Ospedale di Treviso, 31100 Treviso, Italy;
| | - Nicholas Geremia
- Infectious Disease Unit, Ospedale di Venezia, 30122 Venezia, Italy;
| | | | - Yasmine Abi Aad
- Hôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, Cedex 12, 75571 Paris, France; (Y.A.A.); (J.-P.V.); (K.L.)
| | - Jean-Paul Vincensini
- Hôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, Cedex 12, 75571 Paris, France; (Y.A.A.); (J.-P.V.); (K.L.)
| | - Marco Iannetta
- Infectious Disease Unit, Policlinico Tor Vergata of Rome, 00133 Rome, Italy; (T.M.); (E.T.); (M.I.); (L.S.)
- Department of System Medicine, Tor Vergata University of Rome, 00133 Rome, Italy
| | - Saverio Giuseppe Parisi
- Department of Molecular Medicine, University of Padova, 35128 Padova, Italy; (M.B.); (S.G.P.)
| | - Loredana Sarmati
- Infectious Disease Unit, Policlinico Tor Vergata of Rome, 00133 Rome, Italy; (T.M.); (E.T.); (M.I.); (L.S.)
- Department of System Medicine, Tor Vergata University of Rome, 00133 Rome, Italy
| | - Karine Lacombe
- Hôpital Saint-Antoine, Assistance Publique Des Hôpitaux de Paris, Service Des Maladies Infectieuses Et Tropicales, Cedex 12, 75571 Paris, France; (Y.A.A.); (J.-P.V.); (K.L.)
- INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Sorbonne University, 75646 Paris, France
| |
Collapse
|
3
|
Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas. Viruses 2023; 15:v15020373. [PMID: 36851587 PMCID: PMC9965363 DOI: 10.3390/v15020373] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Revised: 01/20/2023] [Accepted: 01/26/2023] [Indexed: 01/31/2023] Open
Abstract
The present-day management of hepatitis B virus (HBV) infection relies on constant and appropriate monitoring of viral activity, disease progression and treatment response. Traditional HBV infection biomarkers have many limitations in predicting clinical outcomes or therapy success. Quantitation of HBV core antibodies (qAnti-HBc) is a new non-invasive biomarker that can be used in solving multiple diagnostic problems. It was shown to correlate well with infection phases, level of hepatic inflammation and fibrosis, exacerbations during chronic infection and presence of occult infection. Further, the level of qAnti-HBc was recognised as predictive of spontaneous or therapy-induced HBeAg and HBsAg seroclearance, relapse after therapy discontinuation, re-infection after liver transplantation and viral reactivation upon immunosuppression. However, qAnti-HBc cannot be relied upon as a single diagnostic test to solve all dilemmas, and its diagnostic and prognostic power can be much improved when combined with other diagnostic biomarkers (HBV DNA, HBeAg, qHBsAg and anti-HBs antibodies). The availability of commercial qAnti-HBc diagnostic kits still needs to be improved. The comparison of results from different studies and definitions of universal cut-off values continue to be hindered because many methods are only semi-quantitative. The clinical utility of qAnti-HBc and the methods used for its measurement are the focus of this review.
Collapse
|
4
|
Special Issue: “Updates on HBV Infection”. Microorganisms 2022; 10:microorganisms10030580. [PMID: 35336155 PMCID: PMC8954355 DOI: 10.3390/microorganisms10030580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 02/09/2022] [Accepted: 03/01/2022] [Indexed: 02/04/2023] Open
|
5
|
Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-Silberstein F, Perno CF, Andreoni M, Svicher V, Sarmati L. Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines 2022; 10:biomedicines10020443. [PMID: 35203653 PMCID: PMC8962433 DOI: 10.3390/biomedicines10020443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 02/03/2022] [Accepted: 02/10/2022] [Indexed: 12/21/2022] Open
Abstract
The role of novel HBV markers in predicting Hepatitis B virus reactivation (HBV-R) in HBsAg-negative/anti-HBc-positive oncohaematological patients was examined. One hundred and seven HBsAg-negative/anti-HBc-positive oncohaematological patients, receiving anti-HBV prophylaxis for >18 months, were included. At baseline, all patients had undetectable HBV DNA, and 67.3% were anti-HBs positive. HBV-R occurred in 17 (15.9%) patients: 6 during and 11 after the prophylaxis period. At HBV-R, the median (IQR) HBV-DNA was 44 (27–40509) IU/mL, and the alanine aminotransferase upper limit of normal (ULN) was 44% (median (IQR): 81 (49–541) U/L). An anti-HBc > 3 cut-off index (COI) plus anti-HBs persistently/declining to <50 mIU/mL was predictive for HBV-R (OR (95% CI): 9.1 (2.7–30.2); 63% of patients with vs. 15% without this combination experienced HBV-R (p < 0.001)). The detection of highly sensitive (HS) HBsAg and/or HBV-DNA confirmed at >2 time points, also predicts HBV-R (OR (95% CI): 13.8 (3.6–52.6); 50% of positive vs. 7% of negative patients to these markers experienced HBV-R (p = 0.001)). HS-HBs and anti-HBc titration proved to be useful early markers of HBV-R. The use of these markers demonstrated that HBV-R frequently occurs in oncohaematological patients with signs of resolved HBV infection, raising issues of proper HBV-R monitoring.
Collapse
Affiliation(s)
| | - Romina Salpini
- Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy; (R.S.); mohammad-- (M.A.); (L.P.); (A.B.); (A.B.); (F.C.-S.); (V.S.)
| | - Mohammad Alkhatib
- Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy; (R.S.); mohammad-- (M.A.); (L.P.); (A.B.); (A.B.); (F.C.-S.); (V.S.)
| | - Vincenzo Malagnino
- Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy; (V.M.); (L.F.); (C.L.); (E.T.); (M.A.)
| | - Lorenzo Piermatteo
- Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy; (R.S.); mohammad-- (M.A.); (L.P.); (A.B.); (A.B.); (F.C.-S.); (V.S.)
| | - Arianna Battisti
- Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy; (R.S.); mohammad-- (M.A.); (L.P.); (A.B.); (A.B.); (F.C.-S.); (V.S.)
| | - Ada Bertoli
- Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy; (R.S.); mohammad-- (M.A.); (L.P.); (A.B.); (A.B.); (F.C.-S.); (V.S.)
| | - Jeff Gersch
- Infectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA; (J.G.); (V.H.); (M.K.); (G.C.)
| | - Vera Holzmayer
- Infectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA; (J.G.); (V.H.); (M.K.); (G.C.)
| | - Mary Kuhns
- Infectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA; (J.G.); (V.H.); (M.K.); (G.C.)
| | - Gavin Cloherty
- Infectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA; (J.G.); (V.H.); (M.K.); (G.C.)
| | - Ludovica Ferrari
- Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy; (V.M.); (L.F.); (C.L.); (E.T.); (M.A.)
| | - Campogiani Laura
- Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy; (V.M.); (L.F.); (C.L.); (E.T.); (M.A.)
| | - Elisabetta Teti
- Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy; (V.M.); (L.F.); (C.L.); (E.T.); (M.A.)
| | - Maria Cantonetti
- Stem Cell Transplant Unit, Department of Hematology, Tor Vergata University, 00133 Rome, Italy; (M.C.); (W.A.)
| | - William Arcese
- Stem Cell Transplant Unit, Department of Hematology, Tor Vergata University, 00133 Rome, Italy; (M.C.); (W.A.)
| | - Francesca Ceccherini-Silberstein
- Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy; (R.S.); mohammad-- (M.A.); (L.P.); (A.B.); (A.B.); (F.C.-S.); (V.S.)
| | | | - Massimo Andreoni
- Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy; (V.M.); (L.F.); (C.L.); (E.T.); (M.A.)
| | - Valentina Svicher
- Department of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy; (R.S.); mohammad-- (M.A.); (L.P.); (A.B.); (A.B.); (F.C.-S.); (V.S.)
| | - Loredana Sarmati
- Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy; (V.M.); (L.F.); (C.L.); (E.T.); (M.A.)
- Correspondence:
| |
Collapse
|
6
|
Wang L, Li L, Li C, Hou Y, Xu M, Yu Y, Ni X, Wang R, Wang H, Wang L, Peng J, Hou M. Significance of anti-HBc serological status in primary immune thrombocytopenia. Br J Haematol 2021; 196:1086-1095. [PMID: 34854079 DOI: 10.1111/bjh.17977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 11/16/2021] [Indexed: 11/30/2022]
Abstract
The association of previous hepatitis B virus (HBV) exposure [hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (anti-HBc/HBcAb) positive] with disease severity and decision on treatment option in primary immune thrombocytopenia (ITP) patients remains unclear. Data from 725 patients diagnosed with ITP were analyzed to elucidate the association between anti-HBc serological status and disease severity. Data from a published prospective study [high-dose dexamethasone (HD-DXM), HD-DXM plus recombinant human thrombopoietin, NCT01734044] and two retrospective studies (standard-dose and low-dose rituximab) were rearranged to evaluate the impact of anti-HBc serological status on the response and outcome to ITP-specific treatments and the risk of HBV reactivation related to these treatments. The prevalence of HBsAg- HBcAb+ and HBsAg- HBcAb- in ITP patients was 51·03% and 48·97% respectively. Compared to the HBsAg- HBcAb- group, patients in the HBsAg- HBcAb+ group had lower platelet count, higher bleeding score, and longer hospitalization (P = 0·002, 0·033, and 0·008 respectively). Moreover, the initial complete response rate of HBsAg- HBcAb+ patients was lower than that of HBsAg- HBcAb- patients (45·2% vs 59·8%, P = 0·027). In conclusion, previous HBV exposure was correlated with disease severity and hospitalization in ITP patients. Anti-HBc positivity may be considered as a predictor for poor response to ITP-specific treatments.
Collapse
Affiliation(s)
- Lingjun Wang
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Lizhen Li
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Chaoyang Li
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Yu Hou
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Miao Xu
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Yafei Yu
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Xiaofei Ni
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Ruting Wang
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Haoyi Wang
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Lin Wang
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Jun Peng
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.,Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Ming Hou
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.,Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital of Shandong University, Jinan, China
| |
Collapse
|
7
|
Mukhatayeva A, Mustafa A, Dzissyuk N, Issanov A, Bayserkin B, Vermund SH, Ali S. Hepatitis B, Hepatitis C, tuberculosis and sexually-transmitted infections among HIV positive patients in Kazakhstan. Sci Rep 2021; 11:13542. [PMID: 34188081 PMCID: PMC8241865 DOI: 10.1038/s41598-021-92688-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 06/07/2021] [Indexed: 11/29/2022] Open
Abstract
In contrast with global trends, HIV prevalence in Kazakhstan and other Central Asian countries has been rising in recent years. In this study, we analyzed hepatitis B (HBV), hepatitis C (HCV), tuberculosis (TB) and sexually-transmitted (STI) co-infections among 500 HIV positive study participants recruited from all regions of Kazakhstan. Among our study participants, 27%, 8%, 2%, and 5% were coinfected with, respectively, HCV, TB, HBV, and STI. A considerable proportion of the study participants was also found with triple or quadruple infections of HCV/TB (12%), TB/STI (0.8%), HCV/STI (2%), HCV/HBV (1%), HBV/TB (0.4%), HBV/STI (0.2%), HBV/HCV/TB (0.4%), HBV/HCV/STI (0.2%), or HCV/TB/STI (0.2%). Strong associations were found of certain age groups, duration of HIV infection, and practices of injection drug use and sexual contact with PLWH, with co-infections of HIV/HCV and HIV/TB. The odds of having death was 4.07 times higher with TB/HIV as compared to other co-infections. Co-occurrence of HIV with HCV, HBV, and TB infections among participants of this study highlights the necessity of regular screening for HCV infection among HIV infected patients, together with implementation of vigilant vaccination protocols against HBV and TB. Additionally, persons who inject drugs especially need to be focused for harm reduction efforts that include opiate substitution therapy, needle or syringe exchange programs, regular screening, and increased availability of ART and direct acting antivirals.
Collapse
Affiliation(s)
- Ainur Mukhatayeva
- Department of Biomedical Sciences, Nazarbayev School of Medicine, Nazarbayev University, Astana, Kazakhstan
| | - Aidana Mustafa
- Department of Biomedical Sciences, Nazarbayev School of Medicine, Nazarbayev University, Astana, Kazakhstan
| | - Natalya Dzissyuk
- Kazakh Scientific Center of Dermatology and Infectious Diseases, Almaty, Kazakhstan
| | - Alpamys Issanov
- Department of Biomedical Sciences, Nazarbayev School of Medicine, Nazarbayev University, Astana, Kazakhstan
| | - Bauyrzhan Bayserkin
- Kazakh Scientific Center of Dermatology and Infectious Diseases, Almaty, Kazakhstan
| | | | - Syed Ali
- Department of Biomedical Sciences, Nazarbayev School of Medicine, Nazarbayev University, Astana, Kazakhstan.
| |
Collapse
|
8
|
Malagnino V, Teti E, Compagno M, Coppola L, Salpini R, Svicher V, Basso M, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, Iannetta M, Parisi SG, Andreoni M, Sarmati L. HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. Microorganisms 2021; 9:microorganisms9020396. [PMID: 33671934 PMCID: PMC7919011 DOI: 10.3390/microorganisms9020396] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 02/09/2021] [Accepted: 02/11/2021] [Indexed: 01/31/2023] Open
Abstract
The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of Human Immunodeficiency Virus (HIV) viremia in patients living with HIV (PLWH) who switch a to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC). A retrospective observational multicenter study was conducted on 166 PLWH switching to the 2DR-3TC-based regimen: 58 HBcAb-positive and 108 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly higher percentage of subjects with very low-level viremia at all time points after switching (6th month: <31% vs. 17.6%, p = 0.047; 12th month 34% vs. 27.5%, p = 0.001; 24th month 37% vs. 34.2, p = 0.003 of the HBcAb-positive and HBcAb-negative groups, respectively) and a higher percentage of subjects with detectable HIV RNA greater than 20 copies/mL 12 and 24 months after switching (12 months 32% vs. 11%, p = 0.001; 24 months 37% vs. 13.9%, p = 0.003 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that an increase in age of ten years (OR 2.48 (95% CI 1.58–3.89), p < 0.0001) and the presence of HBcAb positivity (OR 2.7 (5% CI 1.05–6.9), p = 0.038) increased the risk of detectability of HIV RNA by nearly three-fold after switching to 2DR-3TC.
Collapse
Affiliation(s)
- Vincenzo Malagnino
- Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
- Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy
- Correspondence: ; Tel.: +390-620-902-790
| | - Elisabetta Teti
- Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
| | - Mirko Compagno
- Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
| | - Luigi Coppola
- Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
| | - Romina Salpini
- Dipartimento di Medicina Sperimentale, Università degli Studi di Roma Tor Vergata, 00133 Rome, Italy; (R.S.); (V.S.)
| | - Valentina Svicher
- Dipartimento di Medicina Sperimentale, Università degli Studi di Roma Tor Vergata, 00133 Rome, Italy; (R.S.); (V.S.)
| | - Monica Basso
- Dipartimento di Medicina Molecolare, Università degli Studi di Padova, 35128 Padova, Italy; (M.B.); (D.Z.); (S.G.P.)
| | | | - Sandro Panese
- UOC Malattie Infettive Ospedale di Venezia, 30122 Venezia, Italy;
| | | | - Renzo Scaggiante
- UOC Malattei Infettive, Ospedale di Belluno, 32100 Belluno, Italy;
| | - Daniela Zago
- Dipartimento di Medicina Molecolare, Università degli Studi di Padova, 35128 Padova, Italy; (M.B.); (D.Z.); (S.G.P.)
| | - Marco Iannetta
- Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
- Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy
| | - Saverio Giuseppe Parisi
- Dipartimento di Medicina Molecolare, Università degli Studi di Padova, 35128 Padova, Italy; (M.B.); (D.Z.); (S.G.P.)
| | - Massimo Andreoni
- Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
- Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy
| | - Loredana Sarmati
- Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
- Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy
| |
Collapse
|